N-substituted derivatives of 4 (N-piperazinylmethyl) spiro dibenzocycloheptadi- (or tri-) ene-5, 2-dioxolane (1,3) their method of preparation and their application in therapeutics

Abstract

Compounds of the formula ##STR1## wherein Z is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH--, and R is methyl, ethoxycarbonylmethyl or ##STR2## wherein ##STR3## is methylamino, n-propylamino, isopropylamino, dimethylamino, di(n-propyl)amino, morpholino, pyrrolidino or hexamethyleneimino. The compounds are prepared by reacting piperazine substituted with R, with 4'-bromomethyl-5,2'-spiro-dibenzocycloheptadi(or tri)ene-(1',3') dioxolan. The compounds possess cough-suppressing, spasmolytic, analgesic, respiratory analeptic, hypotensive, vasodilatory, antiarythmic, antiulcerous, antihistamine, sedative, anti-inflammatory, diuretic and antiserotonine properties.

Description

The present invention relates to new N'-substituted derivatives of 4'-(N-piperazinylmethyl)spiro dibenzocycloheptadi- (or tri-) ene-5,2'- dioxolane (1',3').

The compounds have the formula: ##STR4## in which: Z represents a --CH.sub.2 --CH.sub.3 -- group or a --CH.dbd.CH-- group, and

R represents: Methyl, or Ethoxycarbonylmethyl, or Methylaminocarbonylmethyl, propylaminocarbonylmethyl, isopropylaminocarbonylmethyl, dimethylaminocarbonylmethyl, dipropylaminocarbonylmethyl, morpholinocarbonylmethyl, pyrrolidinocarbonylmethyl or hexamethyleneiminocarbonylmethyl, that is, compounds in which R is ##STR5## wherein ##STR6## is methylamino, n-propylamino, isopropylamino, dimethylamino, di(n-propyl)amino, morpholino, pyrrolidino or hexamethyleneimino.

The compounds are prepared reacting the bromomethyl-4'-spiro dibenzocycloheptadi- (or tri-)ene-5,2'-dioxolane (1',3') having as formula ##STR7## on a monosubstituted piperazine having as formula: ##STR8## in which R and Z have the same meaning as in formula (I).

The compound of formula (II) in itself obtained by reacting, in the presence of tin tetrchloride, epibromhydrin having the formula ##STR9## on dibenzo (a-d) cycloheptadi- (or tri-)enone having the formula:

The following preparation is given as a non-limiting example to illustrate the process.

EXAMPLE

4'-N'-(2",3"-dihydroxy "-propyl)N-piperazinyl methyl spiro dibenzo (a,d) cycloheptadiene-5:2' dioxolane (1',3') dimaleate.

Code number: 70405

In 300 ml of CHCl.sub.3 are dissolved 62 g of dibenzocycloheptadienone and 11 g of SnCl.sub.4. This mixture is cooled to 5.degree. C., then 50 g of epibromhydrin in solution in 100 ml of CHCl.sub.3 are slowly introduced; after 3 hours of contact at the same temperature caustic soda lye is added to alkalize the mixture, then the organic phase is washed several times with water. After concentration, a crude product is obtained which is recrystallized in isopropyl alcohol. After recrystallization 92 g of 4'-bromomethyl spiro dibenzo (a,d) cycloheptadiene-5:2' -dioxolane (1',3') are obtained.

In 300 ml of toluene are dissolved 34.5 g of the bromomethylated derivative thus prepared, then 16 g of sodium carbonate and 32 g of N-2,3 dihydroxy 1piperazine are introduced. It is refluxed while stirring for 8 hours, then, after cooling, 500 ml of water and 300 ml of ethyl acetate are added. After decantation, the organic solution is concentrated. The oily crude product obtained is treated in acetone with 23 g of maleic acid. The dimaleace obtained is separated by filtration and recrystallized in ethanol.

Melting point: 179.degree. C.

Yield: 45%

The titre of the compound obtained, as potentiographically determined, is 99%. The water content, as determined by K. Fischer's method is 0.55%. The compounds listed in the following Table I were prepared by the same method of operation.

EXAMPLE 2

-4'-[N'-(di-n-propylaminocarbonylmethyl) N-piperazinyl methyl] spiro [dibenzo(a,d)cycloheptatriene-5:2' dioxolane (1',3')] dimaleate

To a solution of 0.4 mole of N-[di-n-propylaminocarbonylmethyl] piperazine in 500 ml of toluene, under reflux, there is added 0.2 mole of sodium carbonate and then 0.2 mole of bromomethyl-4'-spiro[dibenzocycloheptatriene-5:2' dioxolane (1',3']. Reflux is maintained for 8 hours. After cooling, 500 ml of water and 300 ml of ethyl acetate are added. After decantation, the organic solution is concentrated. The crude product is recrystallized from isopropyl ether. To a solution of 0.12 mole of the thus-obtained compound, in 700 ml of acetone, is added 0.24 mole of maleic acid in 150 ml of acetone. The crude dimaleate thus obtained is separated by filtration and is recrystallized from 400 ml of ethanol.

TABLE I__________________________________________________________________________ ##STR11## Elementary analysisCode Empirical Molecular Melting Calculated Foundnumber R formula weight point yield C H N C H N__________________________________________________________________________70358 CH.sub.3 C.sub.31 H.sub.36 N.sub.2 O.sub.10 596,61 202.degree. C 50% 62.40 6.08 4.70 62.41 6.03 4.8770365 CH.sub.2 COOC.sub.2 H.sub.5 C.sub.34 H.sub.40 N.sub.2 O.sub.12 668.67 156.degree. C 69% 61.07 6.03 4.19 60.96 5.99 4.3070347 ##STR12## C.sub.35 H.sub.43 N.sub.3 O.sub.11 681.71 188.degree. C 39% 61.66 6.36 6.16 61.58 6.31 6.3070357 ##STR13## C.sub.36 H.sub.43 N.sub.3 O.sub.12 709.72 198.degree. C 48% 60.92 6.11 5.92 60.84 6.00 6.1070339 ##STR14## C.sub.36 H.sub.43 N.sub.3 O.sub.11 693.72 174.degree. C 68% 62.32 6.25 6.06 62.41 6.23 6.2670374 ##STR15## C.sub.39 H.sub.40 N.sub.2 O.sub.6 632.72 209.degree. C 31% 74.03 6.37 4.43 74.15 6.25 4.63 ##STR16## Elementary AnalysisCode Empirical Molecular Melting Calculated Foundnumber R formula weight point yield C H N C H N__________________________________________________________________________72143 CH.sub.3 C.sub.31 H.sub.34 N.sub.2 O.sub.10 594.59 176.degree. C 58% 62.62 5.76 4.71 62.50 5.98 4.9172196 CH.sub.2CHOHCH.sub.2 OH C.sub.33 H.sub.38 N.sub.2 O.sub.12 654.65 167.degree. C 44% 60.54 5.85 4.28 60.34 5.95 4.4872188 CH.sub.2CONHCH.sub.3 C.sub.33 H.sub.37 N.sub.3 O.sub.11, 660.65 106.degree. C 23% 59.99 5.80 6.36 59.81 5.71 6.52 H.sub.2 O72134 ##STR17## C.sub.35 H.sub.41 N.sub.3 O.sub.11 679.70 170.degree. C 79% 61.84 6.08 6.18 61.93 6.23 6.377251 ##STR18## C.sub.34 H.sub.39 N.sub.3 O.sub.11 665.67 174.degree. C 70% 61.34 5.91 6.31 61.14 5.88 6.427204 ##STR19## C.sub.30 H.sub.39 N.sub.3 O.sub.3 * C.sub.38 H.sub.47 N.sub.3 O.sub.11 489.83 721.78 107.degree. C 148.degree. C 78% 81% 73.59 63.23 8.03 6.56 8.58 5.82 73.52 65.06 8.12 6.48 8.72 5.8071562 ##STR20## C.sub.36 H.sub.41 N.sub.3 O.sub.11 691.71 160.degree. C 70% 62.51 5.97 6.08 62.51 6.01 5.9371564 ##STR21## C.sub.28 H.sub.33 N.sub.3 O.sub.4 * C.sub.36 H.sub.41 N.sub.3 O.sub.12 475.56 707.71 155.degree. C 153.degree. C 83% 66% 70.71 61.09 6.99 5.84 8.84 5.94 70.83 60.89 7.03 5.88 8.75 5.8572176 ##STR22## C.sub.38 H.sub.45 N.sub.3 O.sub.11 719.76 154.degree. C 49% 63.41 6.22 5.84 63.33 6.34 5.9472142 CH.sub.2CONHC.sub.3 H.sub.7 (.eta.) C.sub.35 H.sub.41 N.sub.3 O.sub.11 679.70 165.degree. C 41% 61.84 6.08 6.18 61.81 6.21 6.30__________________________________________________________________________ *base

The compounds of formula I were studied with laboratory animals and showed antiserotonine, anti-cough, spasmolytic, analgesic and respiratory analeptic, hypotensive, vasodilatory, antiarythmic, antiulcerous, antihistamine, sedative, antiinflammatory and diuretic properties. The compounds of formula I do not exhibit anti-depressive properties.

1. Anti-cough properties

The compounds of formula (I) administered intravenously and intraduodenally reduced the cough caused by stimulation of the upper laryngeal nerve in an anaesthetized cat. The results obtained with a certain number of these compounds are given in the following Table II:

Table II______________________________________Code number of Dose Reduction of coughcompound tested administered intensity duration______________________________________70357 2 mg/kg/IV 100% 20 mm70358 25 mg/kg/ID 100% >60 mm70356 2 mg/kg/IV 100% 90 mm70339 1 mg/kg/IV 100% 20 mm70347 1 mg/kg/IV 80% 20 mm70405 100 mg/kg/ID 100% 60 mm______________________________________

2. Spasmolytic properties

Compounds of formula I, introduced in the survival medium, are capable of opposing the contacting action of barium chloride on the isolated duodenum of a rat. This activity is determined either by taking papaverine as the standard or by calculating the DE.sub.50 of the compound tested. The results obtained with certain of these compounds are given in the following Tables III and IV.

Table III______________________________________Code number ofcompound tested Spasmolytic activity______________________________________70357 1.5 .times. papaverine70358 1.5 .times. papaverine70365 3 .times. papaverine70339 1 .times. papaverine70347 1.5 .times. papaverine______________________________________ Table IV______________________________________Code number of DE.sub.50compound tested .mu.g/ml______________________________________72143 3.7572196 0.257251 3.507204 2.5071564 2.5072176 3.5072142 2.50______________________________________

3. Analgesic properties

The compounds of formula (I) administered orally to a mouse are capable of reducing the number of painful stretchings following the intraperitoneal injection of acetic acid.

By administering 100 mg/kg/PO of different compounds of formula (I) the results shown in the following Table V are obtained.

Table V______________________________________ Percentage reduction inCode number of the number of painfulcompound tested stretchings (%)______________________________________70358 4370365 7570347 7070339 7572196 4572188 60 7251 50 7204 7071562 4772142 70______________________________________

4. Respiratory analeptic properties

The compounds of formula (I) administered intravenously to an anaesthetized guinea pig are capable of opposing respiratory depression caused by morphine. As an example, with a dose of 5 mg/kg/IV, compound 70358 increased respiratory frequency by 65%.

5. Hypotensive properties

Administered intravenously to an anaesthetized rat, the compounds of formula (I) cause a lowering of arterial pressure. The results obtained with a certain number of these compounds are shown in the following Table VI.

Table VI______________________________________ Reduction of arter-Code number of Dose ial pressurecompound tested administered intensity duration______________________________________70374 2 mg/kg/IV 35 % 20 mm70339 1 mg/kg/IV 80 % >30 mm70347 2 mg/kg/IV 50 % >30 mm70405 2 mg/kg/IV 40 % >60 mm______________________________________

6. Antiinflammatory properties

These properties bring about a reduction of the local edema, caused by injecting a rat under the plantar with a phlogogenic agent such as carraghenine, following oral administration of compounds of formula (I). As examples the results obtained with a few of the compounds of formula (I) are given in the following Table VII.

Table VII______________________________________ Dose Percentage reduc-Code number of administered tion of the edemacompound tested (mg/kg/PO) (%)______________________________________72143 30 7072196 100 70______________________________________

7. Vasodilatory properties

The compounds of formula (I) are able to increase the flow in the coronary vessels of the isolated heat of a guinea pig when they are added to the perfusion liquid of this organ. As an example, by adding 0.5 .mu.g/ml of the compound code number 71562 to the perfusion liquid of the isolated heart of a guinea pig, a 45% increase in the flow of the coronary vessels was observed.

8. Antiarythmic properties

Administered intraperitoneally, the compounds of formula (I) are able to protect the mouse against ventricular fibrillations caused by inhaling chloroform. As examples, the results obtained with different compounds of formula (I) are listed in the following Table VIII.

Table VIII______________________________________ Antagonism to fibrillations caused by chloroform with aCode number of mousecompound tested DE.sub.50 (mg/kg/IP)______________________________________72195 6072188 3872134 65 7251 10071562 12571564 20072176 10072142 85 7204 100______________________________________

9. Antiulcerous properties

Compounds of formula (I) administered intraduodenally reduce the size of gastric ulcers caused in a rat by ligature of the pylorus (Shay ulcers). As examples, the intradeuodenal administration of 50 mg/kg of the compounds of code numbers 72143 and 7251 bring about a 70% and 65% reduction respectively of the Shay ulcer.

10. Antihistamine properties

The compounds of formula (I) introduced in the survival medium are able to oppose the contracting action of histamine on the isolated ileum of a guinea pig. This activity is calculated by the DE50 of the tested compounds. The results obtained for different compounds of formula (I) are listed in Table IX below.

Table IX______________________________________ Antihistamine activityCode number of DE50compound tested (.mu.g/ml)______________________________________72143 0.2572196 172188 172134 172176 0.572142 0.6______________________________________

11. Sedative properties

The compounds of formula (I) administered orally to a mouse reduce the number of explorations in the escape enclosure. As examples, the administration of 100 mg/kg/PO of the compounds of code numbers 71562 and 72142 bring about a 40% reduction in the number of explorations in the escape enclosure in each case.

12. Diuretic properties

The compounds of formula (I) administered orally to a mouse simultaneously with a volume of 1 ml of sodium chloride isotonic solute per 25 g of body weight are able to cause an increase of the volume of urine given compared with controls, this volume being measured for the 4 hours following administration. As examples, the results obtained with different compounds of formula (I) are given in Table X below.

Table X______________________________________ Dose Percentage increaseCode number of administered in urinary elimina-compound tested (mg/kg/PO) tion______________________________________72 143 25 7072 196 12.5 4072 188 25 4072 134 50 55 7 251 50 4571 562 50 7071 564 12.5 5072 142 50 55______________________________________

13. Antiserotonine properties

The compounds of formula (I) possess a particularly significant antiserotonine property. This property is exhibited in in vivo tests, i.e. antagonism against bronchoconstrictions provoked by intravenous injection of serotonine to guinea pigs (Konzett and Rossler test), and in in vitro tests, i.e. reduction of the contractions of the isolated fundus of rats and the isolated tied uterus, provoked by serotonine.

For purposes of comparison, compounds of the formula (I) were compared, as to their antiserotonine properties, with a respresentative sampling of compounds disclosed in U.S. Pat. No. 3,726,900. The comparison compounds tested have the formula ##STR23##

The specific compounds tested were as follows:

______________________________________ Code No. Z ##STR24##______________________________________69257 CH.sub.2CH.sub.2 N(CH.sub.3).sub.270301 CHCH ##STR25##70312 CHCH N(CH.sub.3).sub.270315 CHCH ##STR26##______________________________________ the results of comparative tests carried out under the same conditions were as follows: Table XI__________________________________________________________________________Antiserotonine Properties Code Number of compounds tested Test of Konzett and Rossler DE.sub.50 (mg/kg/I.V.) LD.sub.50 (mice) (mg/kg/P.O) ##STR27## Antagonisms against contrac- tions of: Tied uterusFundus of rat DE.sub.50 (g/ml)DE.sub.50__________________________________________________________________________ (g/ml)Compounds of theinvention70.358 -- 1000 -- -- 4.9470.365 0.6 1250 48 6 3.2770.357 0.005 1300 0.38 0.005 0.5470.339 0.1 1200 8.3 0.002 0.6770.347 0.5 1200 41 0.02 1.7872.143 -- 300 -- -- 4.0972.196 -- 1100 -- -- 3.5172.188 0.25 1100 25 -- 2.6172.142 0.6 1650 36 -- 2.1272.134 -- 1200 -- -- 1.7272.51 -- >2000 -- -- 2.6172.04 -- 1900 -- -- 0.0771.562 -- 2000 -- -- 0.171.564 0.05 3500 14 0.001 0.74Compounds of U.S.Patent No.3 726 90069.257 0.40 550 72 -- --70.301 0.40 425 94 -- --70.312 0.43 480 89 -- --70.315 1.40 700 200 -- --__________________________________________________________________________

14. Anti-depressive properties

The compounds of formula (I) demonstrate no activity when tested by the two principal screening tests for antidepressive activity, namely, opposing the ptosis caused by the intravenous injection of reserpine and potentialization of the lethal effect of yohimbine. In this regard, the compounds of formula I differ unexpectedly from the compounds of U.S. Pat. No. 3,726,900, as shown by comparative testing.

The results of these comparative tests were as follows:

Table XII__________________________________________________________________________Anti-Depressive Properties__________________________________________________________________________Code No. of com- LD.sub.50 Antagonism against ptosis Potentialization of lethalpounds tested mg/kg/P.O. caused by reserpine effect of yohimbine__________________________________________________________________________70.358 1000 Inactive at 100 mg/kg/PO 40% at 100 mg/kg/PO70.365 1250 Inactive at 100 mg/kg/PO Inactive at 100 mg/kg/PO70.357 1300 Inactive at 100 mg/kg/PO Inactive at 100 mg/kg/PO70.339 1200 Inactive at 100 mg/kg/PO Inactive at 100 mg/kg/PO70.347 1200 Inactive at 100 mg/kg/PO Inactive at 100 mg/kg/PO70.374 >2000 Inactive at 100 mg/kg/PO Inactive at 100 mg/kg/PO72.143 300 Inactive at 50 mg/kg/PO --72.142 1650 Inactive at 100 mg/kg/PO 40% at 100 mg/kg/PO72.188 1100 Inactive at 50 mg/kg/PO --72.134 1200 Inactive at 50 mg/kg/PO --7251 >2000 Inactive at 50 mg/kg/PO --Compounds of U.S.Pat. No. 3,726,90069.257 550 DE.sub.50 : 35 mg/kg/PO DE.sub.50 : 10 mg/kg/PO70.312 480 DE.sub.50 : 13 mg/kg/PO DE.sub.50 : 46 mg/kg/PO70.315 700 45% at 75 mg/kg/PO --__________________________________________________________________________

The anti-depressive properties of additional analog compounds were tested by the same tests. In these tests, the comparison compounds had the formula ##STR28## The specific compounds tested and the test results are indicated in Table XIII.

Table XIII__________________________________________________________________________Anti-Depressive Properties__________________________________________________________________________ Antagonism against ptosis LD.sub.50 caused by reserpine Potentialization of lethal mg/kg/PO (DE.sub.50 mg/kg/PO) effect of yohimbine__________________________________________________________________________--Z-- = --CH.sub.2 --CH.sub.2 -- R CH.sub.3 850 60 50 mg/kg/PO C.sub.4 H.sub.9 (s) 900 45 .perspectiveto. 40% at 50 mg/kg/PO C.sub.2 H.sub.5 550 .perspectiveto. 50 ----Z-- = --CH = CH--: R CH.sub.3 750 25 29 mg/kg/PO C.sub.2 H.sub.5 375 70 60% at 50 mg/kg/PO C.sub.3 H.sub.7 (i) 550 20% at 50 mg/kg/PO --__________________________________________________________________________

As is shown by the preceding results and by those given in Table XIV below, the difference between pharmacologically active doses and lethal doses is sufficiently great to allow the use of compounds of formula (I) in therapeutics.

Table XIV______________________________________ Dose Percentage ofCode numbers of administered mortality withcompounds tested (mg/kg/PO) mice (%)______________________________________70 357 1300 .perspectiveto. 5070 358 1000 .perspectiveto. 5070 365 1250 .perspectiveto. 5070 374 2000 070 339 1200 .perspectiveto. 5070 347 1200 .perspectiveto. 5070 405 1600 .perspectiveto. 5072 143 300 .perspectiveto. 5072 196 1100 .perspectiveto. 5072 188 1100 .perspectiveto. 5072 134 1200 .perspectiveto. 50 7 251 2000 0 7 204 1900 .perspectiveto. 5071 562 2000 .perspectiveto. 5071 564 3500 .perspectiveto. 5072 176 3400 .perspectiveto. 5072 142 1650 .perspectiveto. 50______________________________________

The compounds of formula I are recommended in the treatment of coughs, vascular and visceral spasms, pains, respiratory depression, hypertension, circulatory insufficiencies, cardiac arythmia, gastroduedenal ulcers, allergies and edemas.

They are administered orally in the form of tablets, pills or gelules containing 25 to 300 mg of active principle (3 to 5 a day) and in the form of a syrup dosed with 0.1 to 2% (3 to 6 soup-spoonfuls a day), parenterally in the form of phials containing 25 to 125 mg of active principle (1 to 3 a day) and rectally in the form of suppositories containing 50 to 200 mg of active principle (1 to 2 a day).

Claims

1. A compound of the formula ##STR29## wherein Z is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH, and the pharmacologically acceptable acid addition salts thereof.

2. A compound of the formula ##STR30## wherein Z is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH--, and the pharmacologically acceptable acid addition salts thereof.

3. A compound as claimed in claim 2 in which Z is --CH.dbd.CH--.

4. A compound of the formula ##STR31## wherein Z is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH--, and the pharmacologically acceptable acid addition salts thereof.

5. A compound as claimed in claim 4 in which Z is --CH.dbd.CH--.

6. A compound of the formula ##STR32## wherein Z is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH--, and the pharmacologically acceptable acid addition salts thereof.

7. A compound as claimed in claim 6 in which Z is --CH.dbd.CH--.